Works matching IS 20445385 AND DT 2024 AND VI 14
Results: 227
Integration of clinical outcomes and molecular features in extramedullary disease in multiple myeloma.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01190-9
- By:
- Publication type:
- Article
Global disparities in drug-related adverse events of patients with multiple myeloma: a pharmacovigilance study.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01206-4
- By:
- Publication type:
- Article
Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01200-w
- By:
- Publication type:
- Article
Single-cell transcriptomic and spatial analysis reveal the immunosuppressive microenvironment in relapsed/refractory angioimmunoblastic T-cell lymphoma.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01199-0
- By:
- Publication type:
- Article
Transcriptomic clustering of chronic lymphocytic leukemia: molecular subtypes based on Bruton's tyrosine kinase expression levels.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01196-3
- By:
- Publication type:
- Article
Expanded tumor-associated polymorphonuclear myeloid-derived suppressor cells in Waldenstrom macroglobulinemia display immune suppressive activity.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01173-w
- By:
- Publication type:
- Article
Molecular monitoring in CML—a modern example of an old proverb.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01192-7
- By:
- Publication type:
- Article
Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM.
- Published in:
- Blood Cancer Journal, 2024, v. 14, p. 1, doi. 10.1038/s41408-024-01200-w
- By:
- Publication type:
- Article
Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health database.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01170-z
- By:
- Publication type:
- Article
Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01193-6
- By:
- Publication type:
- Article
A comparative analysis of transformed indolent lymphomas and de novo diffuse large B-cell lymphoma: a population-based cohort study.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01194-5
- By:
- Publication type:
- Article
Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01195-4
- By:
- Publication type:
- Article
Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01197-2
- By:
- Publication type:
- Article
High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01185-6
- By:
- Publication type:
- Article
Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01149-w
- By:
- Publication type:
- Article
CAR-T cell therapy in Multiple Myeloma: current status and future challenges.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01191-8
- By:
- Publication type:
- Article
RSK1 dependency in FLT3-ITD acute myeloid leukemia.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01187-4
- By:
- Publication type:
- Article
Indolent nodal T follicular helper cell lymphomas—A case series.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01163-y
- By:
- Publication type:
- Article
Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) in elder or intensive chemotherapy ineligible patients with newly diagnosed acute myeloid leukemia.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01189-2
- By:
- Publication type:
- Article
What have we learned about TP53-mutated acute myeloid leukemia?
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01186-5
- By:
- Publication type:
- Article
Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01179-4
- By:
- Publication type:
- Article
Impact of TP53 mutation on genetic and cellular hierarchy profile in complex karyotype AML/MDS with increased blasts.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01188-3
- By:
- Publication type:
- Article
A simplified, two-factor clinical prognostic scoring system for patients with newly diagnosed Hodgkins Lymphoma.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01184-7
- By:
- Publication type:
- Article
Genetically determined telomere length in monoclonal gammopathy of undetermined significance, multiple myeloma risk and outcome.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01181-w
- By:
- Publication type:
- Article
Impact of lenalidomide-bortezomib-dexamethasone induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect® MM Registry.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01177-6
- By:
- Publication type:
- Article
Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01183-8
- By:
- Publication type:
- Article
Proteasome inhibitors related thrombotic microangiopathy: a systematic and comprehensive review.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01182-9
- By:
- Publication type:
- Article
The third generation AKR1C3-activated prodrug, ACHM-025, eradicates disease in preclinical models of aggressive T-cell acute lymphoblastic leukemia.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01180-x
- By:
- Publication type:
- Article
Neutrophil-to-lymphocyte ratio as a prognostic indicator of mortality in Polycythemia Vera: insights from a prospective cohort analysis.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01176-7
- By:
- Publication type:
- Article
Mosaic chromosomal alterations (mCAs) in individuals with monoclonal B-cell lymphocytosis (MBL).
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01175-8
- By:
- Publication type:
- Article
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01172-x
- By:
- Publication type:
- Article
Venous thromboembolism in adolescents and young adults with acute lymphoblastic leukemia treated on a pediatric-inspired regimen.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01178-5
- By:
- Publication type:
- Article
Genomic profiles and outcomes in de novo versus therapy-related core binding factor AML.
- Published in:
- 2024
- By:
- Publication type:
- Letter
Optimal infused CD34<sup>+</sup> cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01165-w
- By:
- Publication type:
- Article
Thrombosis in myeloproliferative neoplasms: a viewpoint on its impact on myelofibrosis, mortality, and solid tumors.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01169-6
- By:
- Publication type:
- Article
Drug development in higher-risk myelodysplastic syndromes.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01171-y
- By:
- Publication type:
- Article
The DLEU2/miR-15a/miR-16-1 cluster shapes the immune microenvironment of chronic lymphocytic leukemia.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01142-3
- By:
- Publication type:
- Article
Publisher Correction: Patient preferences for intervention in the setting of precursor multiple myeloma.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Patient preferences for intervention in the setting of precursor multiple myeloma.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01161-0
- By:
- Publication type:
- Article
Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01160-1
- By:
- Publication type:
- Article
Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01155-y
- By:
- Publication type:
- Article
Appraising ascorbic acid as a chemoprevention agent for acute myeloid leukaemia using Mendelian Randomisation.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01168-7
- By:
- Publication type:
- Article
Evaluation of Ki-67 expression and large cell content as prognostic markers in MZL: a multicenter cohort study.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01162-z
- By:
- Publication type:
- Article
Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01167-8
- By:
- Publication type:
- Article
Impact of age on treatment utilization for newly diagnosed multiple myeloma: a nationwide retrospective cohort study.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01164-x
- By:
- Publication type:
- Article
Patient preferences for intervention in the setting of precursor multiple myeloma.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01161-0
- By:
- Publication type:
- Article
Patterns of progression in a contemporary cohort of 447 patients with smoldering multiple myeloma.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01159-8
- By:
- Publication type:
- Article
Clonal dynamics of aggressive systemic mastocytosis on avapritinib therapy.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01157-w
- By:
- Publication type:
- Article
Acute lymphoblastic leukemia in patients treated with lenalidomide for multiple myeloma: a safety meta-analysis of randomized controlled trials combined with a retrospective study of the WHO's pharmacovigilance database.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01154-z
- By:
- Publication type:
- Article
Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01148-x
- By:
- Publication type:
- Article